Probatebeta
Target

F11

Coagulation factor XI

As of the edition of 20 October 2026, F11 (coagulation factor XI, UniProt P03951) has 16 drugs tested at it and 17 companies on the list, 3 on route A and 0 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P03951
How well studied
Chemical tools exist; no approved drug acts on it
Where it sits in the cell
Secreted
Solved structures
123
Disease areas
Heart and blood vessels; Immune system; Skin and connective tissue; Inherited and neonatal; Nervous system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
Registered trials of its drugs
97

Drugs at this target

StatusCount
Marketed1
Active6
Went quiet4
Stopped3
Status not established2
Total16
DrugStatusFurthest phaseUS protection
MilvexianActivePhase 3none listed
Human c1-esterase inhibitorMarketedPhase 4Ended 2025
REGN7508ActivePhase 3none listed
REGN9933ActivePhase 3none listed
AbelacimabActivePhase 3none listed
SHR-2004ActivePhase 3none listed
SHR2285StoppedPhase 2none listed
GruticibartStoppedPhase 2none listed
SRSD107ActivePhase 2none listed
MAA868Went quietPhase 2none listed
OsocimabStatus not establishedPhase 2none listed
FrunexianStoppedPhase 2none listed

12 of 16 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A3
Engaged9
Undetermined5
Total on the list17
Three companies on route A or B, with the route only
CompanyRoute
Hengrui PharmaceuticalRoute A
Akcea TherapeuticsRoute A
Ono PharmaceuticalRoute A

The other 14 companies at F11

In the product

17 companies in all; 14 are not named here, and no score is.

See the 17 companies at F11, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at F11

Other targets in heart and blood vessels